Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Elsamitrusin · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Elsamitrusin | DRUG | - |
Inclusion Criteria: * Histologically confirmed NHL both B and T-cell that is refractory to or has relapsed after standard therapy or for which there is no known effective treatment. * CT or MRI scans confirming measurable tumor size (lymph node must be \>1.0 cm in its longest transverse diameter). ...
Elsamitrusin is an investigational small molecule being studied for the treatment of Non-Hodgkin's Lymphoma. It is currently in Phase 2 clinical development and has been evaluated in patients with relapsed or refractory Non-Hodgkin's Lymphoma.
Elsamitrusin is being developed by Assertio Holdings, Inc., a company traded on the stock exchange under the ticker symbol ASRT. The drug is currently in Phase 2 clinical development for Non-Hodgkin's Lymphoma.
Elsamitrusin is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 2 clinical trial has been completed to evaluate its use in patients with relapsed or refractory Non-Hodgkin's Lymphoma.
Elsamitrusin has been studied in a completed Phase 2 clinical trial with the identifier NCT00184080. This trial evaluated the drug in patients with relapsed or refractory Non-Hodgkin's Lymphoma and enrolled 7 participants in the United States.
Yes, Elsamitrusin is also known as SPP 28090. In clinical trials, the drug has been referred to as Elsamitrucin (SPP 28090), indicating that both names refer to the same investigational drug being developed for Non-Hodgkin's Lymphoma.